文献速递淋巴瘤造血干细胞移植与细胞治疗

靶向趋化因子受体CCR4的嵌合抗原受体修饰T细胞作为T细胞恶性肿瘤的治疗手段

Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.
PubMed 文献 · Am J Hematol · 2017-06-05

为T细胞恶性肿瘤开发靶向CCR4的慢病毒CAR基因转移系统,体外修饰的供者来源T细胞表达CCR4 CAR后,对ATL、CTCL、ALCL及部分HDL患者来源细胞系显示抗原依赖性细胞毒性,并在ATL小鼠异种移植模型中清除白血病。

要点

  • 构建慢病毒CAR基因转移系统,使供者T细胞表达靶向CCR4的CAR。
  • CCR4 CAR T细胞对ATL、CTCL、ALCL及部分HDL患者来源细胞系显示抗原依赖性细胞毒性。
  • CCR4 CAR T细胞在ATL小鼠异种移植模型中清除白血病。

核心结论

  • 靶向CCR4的CAR T细胞在体外和ATL小鼠异种移植模型中显示抗T细胞恶性肿瘤活性,提示该手段可用于治疗广谱T细胞恶性肿瘤。

研究设计与样本

  • 研究建立慢病毒CAR基因转移系统,制备表达CCR4定向CAR的供者来源T细胞,并在患者来源细胞系和小鼠异种移植模型中进行评价。

主要发现

  • 体外修饰的供者来源T细胞表达CCR4定向CAR后,对代表ATL、CTCL、ALCL及部分HDL的患者来源细胞系显示抗原依赖性细胞毒性。
  • CCR4 CAR T细胞在ATL小鼠异种移植模型中清除白血病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the emerging success of treating CD19 expressing B cell malignancies with ex vivo modified, autologous T cells that express CD19-directed chimeric antigen receptors (CAR), there is intense interest in expanding this evolving technology to develop effective modalities to treat other malignancies including solid tumors. Exploiting this approach to develop a therapeutic modality for T cell malignancies for which the available regimens are neither curative, nor confer long term survival we generated a lentivirus-based CAR gene transfer system to target the chemokine receptor CCR4 that is over-expressed in a spectrum of T cell malignancies as well as in CD4+ CD25+ Foxp3+ T regulatory cells that accumulate in the tumor microenvironment constituting a barrier against anti-tumor immunity. Ex vivo modified, donor-derived T cells that expressed CCR4 directed CAR displayed antigen-dependent potent cytotoxicity against patient-derived cell lines representing ATL, CTCL, ALCL and a subset of HDL. Furthermore, these CAR T cells also eradicated leukemia in a mouse xenograft model of ATL illustrating the potential utility of this modality in the treatment of a wide spectrum of T cell malignancies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Perera LP, Zhang M, Nakagawa M, et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol. 2017. PMID: 28543380. doi:10.1002/ajh.24794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。